Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1959 1
1960 1
1974 1
1975 1
1976 1
1977 1
1978 1
1979 5
1980 3
1981 2
1982 7
1983 7
1984 8
1985 8
1986 9
1987 10
1988 9
1989 7
1990 11
1991 15
1992 26
1993 21
1994 19
1995 30
1996 17
1997 25
1998 39
1999 31
2000 33
2001 50
2002 50
2003 57
2004 56
2005 59
2006 73
2007 75
2008 88
2009 63
2010 65
2011 76
2012 74
2013 98
2014 89
2015 107
2016 96
2017 99
2018 116
2019 138
2020 165
2021 204
2022 201
2023 209
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

2,418 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Dermatitis, atopic, 6"
Page 1
Epidemiology of atopic dermatitis in adults: Results from an international survey.
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M, Eckert L. Barbarot S, et al. Allergy. 2018 Jun;73(6):1284-1293. doi: 10.1111/all.13401. Epub 2018 Feb 13. Allergy. 2018. PMID: 29319189
BACKGROUND: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). OBJECTIVE: To estimate the prevalence of AD in adults and by disease severity. ...Regional variability was observed within countries. Severity varied by scale and r …
BACKGROUND: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). OBJECTIVE: To estimate the prev …
Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis.
Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Koskeridis F, et al. J Cutan Med Surg. 2022 Nov-Dec;26(6):613-621. doi: 10.1177/12034754221130969. Epub 2022 Oct 9. J Cutan Med Surg. 2022. PMID: 36214355 Review.
Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and psychosocial comorbidities decreasing the quality of life for many patients. ...Fourteen trials were included: twelve in adults (n = 3,817) and two in children/adolescents (n = 618 …
Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and psychosocial comorbidities decreasing th …
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, Sullivan-Whalen M, Singer GK, Garcet S, Pavel AB, Lebwohl MG, Krueger JG. Guttman-Yassky E, et al. Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6. Allergy. 2022. PMID: 34460948 Free PMC article. Clinical Trial.
Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved for type 2 diseases including atopic dermatitis, was evaluated in AA patients. METHODS: Alopecia areata patients with and without concomitant atopic dermatitis were randomized 2:1 to r …
Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved for type 2 diseases including atopic dermatitis, was evalu …
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL. Papp K, et al. J Am Acad Dermatol. 2021 Oct;85(4):863-872. doi: 10.1016/j.jaad.2021.04.085. Epub 2021 May 4. J Am Acad Dermatol. 2021. PMID: 33957195 Free article. Clinical Trial.
METHODS: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients aged 12 years with AD for 2 years, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area. ...The p …
METHODS: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients …
Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
Sedeh FB, Henning MAS, Jemec GBE, Ibler KS. Sedeh FB, et al. Acta Derm Venereol. 2022 Aug 24;102:adv00764. doi: 10.2340/actadv.v102.2075. Acta Derm Venereol. 2022. PMID: 35818735 Free PMC article.
All randomized controlled trials investigating the efficacy of systemic treatments for moderate-to-severe atopic dermatitis in adults were included. Primary outcomes were the proportion of patients with atopic dermatitis achieving 50%, 75%, and 90% imp …
All randomized controlled trials investigating the efficacy of systemic treatments for moderate-to-severe atopic dermatitis in …
Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis RN, LeBovidge J, Wang J, Ong PY, Lio P, Gutierrez A, Capozza K, Martin SA, Frazier W, Wheeler K, Boguniewicz M, Spergel JM, Greenhawt M, Silverberg JI, Schneider L, Chu DK. Oykhman P, et al. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2657-2666.e8. doi: 10.1016/j.jaip.2022.06.044. Epub 2022 Jul 19. J Allergy Clin Immunol Pract. 2022. PMID: 35987995
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has conflicting views. ...RESULTS: Ten RCT (n = 599; baseline median of study mean age, 1.5 years; median of study mean SCOring Atopic …
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has …
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Chiesa Fuxench ZC. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018 Sep;121(3):340-347. doi: 10.1016/j.anai.2018.07.006. Epub 2018 Jul 16. Ann Allergy Asthma Immunol. 2018. PMID: 30025911 Free article.
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is not well established. ...METHODS: A cross-sectional, population-based study of 602 adults was performed. Atopic dermatitis was …
BACKGROUND: The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in the United States population is n …
Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers.
He H, Olesen CM, Pavel AB, Clausen ML, Wu J, Estrada Y, Zhang N, Agner T, Guttman-Yassky E. He H, et al. Front Immunol. 2020 Aug 6;11:1768. doi: 10.3389/fimmu.2020.01768. eCollection 2020. Front Immunol. 2020. PMID: 32849633 Free PMC article.
Tape-stripping is a minimally invasive approach for skin sampling that captures the cutaneous immune/barrier abnormalities in atopic dermatitis (AD). However, tape-strips have not been used to evaluate molecular changes with therapeutic targeting. ...Using criteria …
Tape-stripping is a minimally invasive approach for skin sampling that captures the cutaneous immune/barrier abnormalities in atopic …
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, Murrell DF, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A. Silverberg JI, et al. J Allergy Clin Immunol. 2020 Jan;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013. Epub 2019 Aug 23. J Allergy Clin Immunol. 2020. PMID: 31449914 Free article. Clinical Trial.
BACKGROUND: Nemolizumab targets the IL-31 receptor alpha subunit involved in atopic dermatitis (AD) pathogenesis. OBJECTIVE: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD. ...Standard safety assessments were performed. RESULTS: Nemol …
BACKGROUND: Nemolizumab targets the IL-31 receptor alpha subunit involved in atopic dermatitis (AD) pathogenesis. OBJECTIVE: W …
Atopic dermatitis across the life course.
Abuabara K, Langan SM. Abuabara K, et al. Br J Dermatol. 2023 May 24;188(6):709-717. doi: 10.1093/bjd/ljac072. Br J Dermatol. 2023. PMID: 36715326
Atopic dermatitis, the most common chronic inflammatory skin disease, can occur at any age, and patterns of disease activity vary over time. ...Parental history of atopy and genetic factors are among the most consistent predictors of more persistent disease. …
Atopic dermatitis, the most common chronic inflammatory skin disease, can occur at any age, and patterns of disease activity v …
2,418 results